Key screening indicators, including the number of metastatic tumors, cN stage, mutations in KRAS and BRAF genes, patient age, primary tumor site, neutrophil count, platelet count, and D-Dimer levels, were integrated into the dynamic prediction model to forecast OS and DFS in patients with resectable synchronous CRLM. The gene discussed is KRAS; the disease is neoplasm.